medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (4)


Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014

Antwi SO, Mousa OY, Patel T

Idioma: Ingles.
Referencias bibliográficas: 42
Paginas: 604-614
Archivo PDF: 181.19 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 2014; 149: 565-74.

  2. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009; 33: 1247-54.

  3. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population- based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-8.

  4. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-89.

  5. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76.

  6. Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PloS One 2013; 8:e69981.

  7. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-25.

  8. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatol 2001; 33: 1353-7.

  9. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006; 26: 1047-53.

  10. Mosadeghi S, Liu B, Bhuket T, Wong RJ. Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. Hepatol Res 2016; 46: 669-77.

  11. Chang K-Y, Chang J-Y, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423-7.

  12. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-20.

  13. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368-78.

  14. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 2002; 22: 3637-41.

  15. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.

  16. The National Cancer Institute Cancer Statistics Branch Surveillance Epidemiology and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 18 Registries. Public- Use Available at: https://seer.cancer.gov.

  17. Howlander N. SEER Cancer Statistics Review 1975-2004. Available at: https://seer.cancer.gov/archive/csr/1975_2004.

  18. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med 2009; 28: 3670-82.

  19. Fox J. Cox proportional-hazards regression for survival data. An R and S-PLUS companion to applied regression. Available at: http://cran.r-project.org/doc/contrib/Fox-Companion/ appendix-cox-regression.pdf.

  20. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-5.

  21. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-7.

  22. Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma—frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol 2011; 137: 1071-8.

  23. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol 2010; 2: 407-16.

  24. Nakanuma Y, Sripa B, Vatanasapt V, Leong A, Ponchon T, Ishak K. Intrahepatic cholangiocarcinoma. WHO Classification of Tumours Pathology and Genetics of Tumours of the Digestive system 2000: 173-80.

  25. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudio E, et al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer 2012; 1: 21-32.

  26. Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, Lee SA, et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol 2010; 17: 1823-30.

  27. Yamamoto M, Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today 2011; 41: 896-902.

  28. Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2014; 23: 231-46.

  29. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56: 848-54.

  30. Tyson GL, Ilyas JA, Duan Z, Green LK, Younes M, El-Serag HB, Davila JA. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 2014; 59: 3103-10.

  31. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013; 57: 648-55.

  32. Allison WE, Chiang W, Rubin A, O’Donnell L, Saldivar MA, Maurantonio M, Dela Cruz J, et al. Hepatitis C virus infection in the 1945-1965 birth cohort (baby boomers) in a large urban ED. Am J Emerg Med 2016; 34: 697-701.

  33. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, Hassan MM. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-21.

  34. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-84.

  35. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J astroenterol Hepatol 2007; 19: 615-17.

  36. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T. Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat 2010; 17: 742-8.

  37. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6: 101- 4.

  38. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010; 101: 579-85.

  39. Khan S, Toledano M, Taylor-Robinson S. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10: 77-82.

  40. Zhou YM1, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14: 632.

  41. The United States Department of Commerce, Economics and Statistics Administration; U. S. Census Bureau. Overview of Race and Hispanic Origin: 2010. Economics and Statistics Administration. Available at: http://www.census.gov/prod/ cen2010/briefs/c2010br-02.pdf.

  42. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, Jemal A. Cancer statistics for Hispanics/ Latinos, 2015. CA Cancer J Clin 2015; 65: 457-80.




2020     |     www.medigraphic.com